Top 10 stocks for today - 31st January 2024

31 Jan 2024 , 08:15 AM

1. L&T: The company is expected to conclude the year with a growth in order inflow exceeding 20%. The company had initially projected a 12% increase in order inflow for the fiscal year 2024. There is a potential for revenue growth in the high teens, surpassing the upper limit of the revenue growth guidance range of 12% to 15%, CNBC TV 18 reported.
2. SRF: The quarterly financial figures fell below estimates, primarily due to the underperformance of the Chemicals business. The EBITDA margin decreased to 18.5% from 24% last year, falling short of the expected 19.6% as per the polls. EBITDA experienced a significant decline of 32.1%, leading to a 50% reduction in net profit.
3. Blue Star: Impressive results surpassed expectations with a 24% increase in revenue, reaching ₹2,241 Crore, exceeding the poll projection of ₹2,128 Crore. EBITDA also exhibited a robust performance, rising by 48% to ₹155 Crore, surpassing the poll estimate of ₹145 Crore.
4. PNB Fintech: The net profit after tax stands at ₹37 Crore, marking a significant turnaround from the net loss of ₹87 Crore reported last year. This mark the first quarter of achieving a positive PAT. The total revenue has surged by 43% year-on-year, reaching ₹871 Crore.
5. Dr Reddy’s Lab: Revenue increased by 7% to ₹7,214.8 Crore, surpassing the estimated ₹6,903.6 Crore. Additionally, EBITDA, margin, and net profit exceeded expectations. US sales reached $403 Million, surpassing the estimated $355 Million and showing growth from the $382 Million reported in the September quarter.
6. Ramakrishna Forgings: The company has raised its corporate guarantee from $2 Million to $3.5 Million for Ramkrishna Forgings LLC, a wholly-owned subsidiary. This increase is aimed at assisting the subsidiary in fulfilling its working capital needs.
7. TCS: The company has extended and broadened its collaboration with Aviva through the establishment of a new 15-year agreement in the United Kingdom.
8. M&M Financials: During the earnings call, the management revised its guidance, stating that achieving the RoA target of 2.5% by the financial year 2025 would be challenging due to weak Net Interest Margins (NIMs). The management anticipates that NIMs will be softer than initially projected.
9. Astral: The revenue stands at ₹1,371 Crore, falling short of the estimated ₹1,436 Crore. However, EBITDA increased by 12.8% to ₹204.6 Crore, though it too is below the estimated figures. Within the segments, the plumbing segment revenue saw a 7.1% increase from last year, while paints and adhesives revenue recorded a growth of 10.7%.
10. Aarti Drugs: The company has commenced commercial production of a Dermatology product at its newly established facility in Tarapur, Maharashtra. This expansion is in line with the company’s strategic vision to reinforce its presence in the skincare segment.

For feedback and suggestions, write to us at [e-mail]